AMVUTTRA® (vutrisiran)
Full Prescribing Information for AMVUTTRA® (vutrisiran)
Explore a range of clinical and educational resources related to the use of vutrisiran in adult patients with the polyneuropathy of ATTRv (also known as hATTR) amyloidosis or with the cardiomyopathy of wild-type or ATTRv amyloidosis.
If you require any further information on vutrisiran, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.
More Information About Vutrisiran
For more information about data regarding vutrisiran, please visit our Congresses and Publications resources page.
RNAi Data Navigator: Focus on Vutrisiran
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
ATTR-CM HELIOS-B Data Summary
ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.
Slide Deck
HELIOS-B Plain Language Summary
This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)
Plain Language Summary
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Slide Deck
